Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 19/20 | 0.81 |
| ▸ | ICAM1 | P05362 | 19/20 | 0.81 |
| ▸ | ITGAL | P20701 | 19/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13658128 | 0.90 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL22296990 | 0.85 | ITGB2 (0.80) | ITGB2ICAM1ITGAL | |
| SCHEMBL13662081 | 0.82 | ITGB2 (0.65) | ITGB2ICAM1ITGAL | |
| SCHEMBL13662126 | 0.82 | ITGB2 (0.62) | ITGB2ICAM1ITGAL | |
| SCHEMBL13662092 | 0.80 | ITGB2 (0.62) | ITGB2ICAM1ITGAL | |
| SCHEMBL13666672 | 0.79 | ITGB2 (0.56) | ITGB2ICAM1ITGAL | |
| SCHEMBL18362419 | 0.79 | ITGB2 (0.78) | ITGB2ICAM1ITGAL | |
| SCHEMBL13668401 | 0.79 | ITGB2 (0.58) | ITGB2ICAM1ITGAL | |
| SCHEMBL18867795 | 0.78 | ITGB2 (0.69) | ITGB2ICAM1ITGALHDAC6 | |
| SCHEMBL13665300 | 0.78 | ITGB2 (0.75) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009128934-A1 | TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS | SARCODE CORPORATION (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090257957-A1 | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090258069-A1 | Delivery of LFA-1 antagonists to the gastrointestinal system | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258069-A1 | Delivery of LFA-1 antagonists to the gastrointestinal system | VCAM1, ITGAL, HAVCR2 | ITGB2 12/4885ICAM1 4/4885ITGAL 2/4885 |
| US-20090257957-A1 | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders | ICAM1, ITGAL, ITGA1 | ITGB2 9/4885ICAM1 1/4885ITGAL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.